Guardant Health, Inc. (NASDAQ:GH) Director Musa Tariq Sells 2,320 Shares

Guardant Health, Inc. (NASDAQ:GH) Director Musa Tariq sold 2,320 shares of the company’s stock in a transaction on Friday, December 13th. The stock was sold at an average price of $35.00, for a total transaction of $81,200.00. Following the transaction, the director now owns 2,676 shares of the company’s stock, valued at approximately $93,660. This represents a 46.44 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.

Guardant Health Trading Up 2.5 %

NASDAQ:GH traded up $0.86 during mid-day trading on Monday, hitting $35.62. 1,839,591 shares of the stock traded hands, compared to its average volume of 2,038,397. The company has a quick ratio of 5.85, a current ratio of 6.22 and a debt-to-equity ratio of 16.70. Guardant Health, Inc. has a 52 week low of $15.81 and a 52 week high of $38.53. The stock has a market capitalization of $4.40 billion, a price-to-earnings ratio of -8.40 and a beta of 1.26. The firm’s 50 day moving average is $27.92 and its two-hundred day moving average is $28.16.

Guardant Health (NASDAQ:GH) last released its earnings results on Wednesday, November 6th. The company reported ($0.88) EPS for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.33). Guardant Health had a negative net margin of 74.02% and a negative return on equity of 1,200.44%. The business had revenue of $191.48 million for the quarter, compared to the consensus estimate of $170.49 million. During the same period in the prior year, the company posted ($0.73) EPS. The company’s quarterly revenue was up 33.9% compared to the same quarter last year. On average, equities research analysts predict that Guardant Health, Inc. will post -3.44 earnings per share for the current year.

Analysts Set New Price Targets

Several analysts have commented on the stock. Sanford C. Bernstein decreased their price target on shares of Guardant Health from $40.00 to $35.00 and set an “outperform” rating on the stock in a research note on Wednesday, October 30th. The Goldman Sachs Group boosted their target price on Guardant Health from $32.00 to $36.00 and gave the stock a “buy” rating in a research report on Thursday, November 7th. Leerink Partners dropped their price target on Guardant Health from $60.00 to $50.00 and set an “outperform” rating for the company in a research note on Thursday, October 17th. JPMorgan Chase & Co. lifted their price objective on Guardant Health from $48.00 to $50.00 and gave the stock an “overweight” rating in a research note on Thursday, November 7th. Finally, UBS Group upped their price objective on Guardant Health from $32.00 to $40.00 and gave the stock a “buy” rating in a report on Wednesday, August 21st. Fifteen equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus target price of $40.60.

Institutional Trading of Guardant Health

Institutional investors and hedge funds have recently made changes to their positions in the business. Cerity Partners LLC increased its stake in Guardant Health by 54.6% in the 3rd quarter. Cerity Partners LLC now owns 195,008 shares of the company’s stock worth $4,473,000 after buying an additional 68,883 shares during the period. Lord Abbett & CO. LLC bought a new position in Guardant Health in the 3rd quarter worth about $15,624,000. Sumitomo Mitsui Trust Group Inc. grew its stake in Guardant Health by 1,282.5% in the 3rd quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,226,176 shares of the company’s stock worth $28,128,000 after acquiring an additional 1,137,482 shares in the last quarter. First Light Asset Management LLC increased its position in shares of Guardant Health by 119.7% during the second quarter. First Light Asset Management LLC now owns 416,967 shares of the company’s stock worth $12,042,000 after acquiring an additional 227,202 shares during the period. Finally, Pier Capital LLC raised its stake in shares of Guardant Health by 36.7% during the third quarter. Pier Capital LLC now owns 158,429 shares of the company’s stock valued at $3,634,000 after acquiring an additional 42,575 shares in the last quarter. 92.60% of the stock is currently owned by institutional investors.

About Guardant Health

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.